Therapy of bone metastases with beta emitters

The use of beta-emitters is broadly discussed in the literature. Their efficacy in relieving and controlling bone pain was largely ascertained and consolidated over the years, in particular for 89 Strontium ( 89 Sr)-Chloride and 153 Samarium (153 Sm)-EDTMP, as well as their good safety profile that renders these radiopharmaceuticals suitable and reliable in the clinical practice. Nowadays, even if the attention has shifted toward alpha-emitting radiopharmaceuticals, the use of beta-emitters may still represent an important therapeutical option for controlling pain in patients affected by metastatic bone disease, especially from prostate and breast cancer.